1

Forward-Looking Statements
Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These
statements relate to future events or the Companys future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the
Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In
some cases, forward-looking statements can be identified by terminology such as may, will, could, would,
should, expect, plan, anticipate, intend, believe, estimate, predict, potential or other comparable
terminology. All statements other than statements of historical fact could be deemed forward-looking, including any
expectations regarding investment returns; any projections of financial information; any statements about historical
results that may suggest trends for our business; any statements of the plans, strategies, and objectives of management
for future operations; any statements of expectation or belief regarding future events, potential markets or market size,
or technology developments; and any statements of assumptions underlying any of the items mentioned. The Company
has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While
the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking
statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the
Companys control. These and other important factors may cause actual results, performance or achievements to differ
materially from those expressed or implied by these forward-looking statements. These statements may involve risks
and uncertainties that could cause actual results to differ materially from the expected results. Such risks include but
are not limited to the risk factors set forth in the Companys most recent Form 10-K, Form 10-Q and other filings with the
Securities and Exchange Commission (SEC). Investors are urged to review the Companys SEC filings. The forward-
looking statements in this presentation are made only as of the date hereof. Except as required by law, the Company
assumes no obligation and does not intend to update these forward-looking statements or to conform these statements
to actual results or to changes in the Company's expectations.

2
 NASDAQ: IVTY

Philip Sawyer, Chief Executive Officer

Jim Mackaness, Chief Financial Officer

3
 Visionary Surgery

4
 Company Snapshot*

Platform of Technologies-illumination, energy, fluorescence

331,000 Procedures

~85% of Revenue from SingleUse Devices

~$2.0B US Market

~23% Revenue Growth YTD 2017 vs. YTD 2016

5
*As of Sept 30, 2017
Minimal Access
Surgery
Advantages:
smaller surgical scars
fewer infections
reduced blood loss
shorter procedure times
faster return to normal activity

Large number of surgical procedures that cant be done laparoscopically or

robotically
 Poor
visualization

Outdated
electrosurgical
technology
Limited access
to advantages of
fluorescence

7 7
 Invuitys System Enables Minimal Access Surgery

Retraction-based Aspiration-based
Illumination Illumination

Dynamic Precision
Illuminator with
Enhanced Energy Fluorescence

8 8
 01.
SOLID CORE
OPTICAL POLYMER

02.
TOTAL INTERNAL
REFLECTION AND LIGHT
MIXING

Intelligent Photonics
Technology
03.
REFRACTIVE
MICROSTRUCTURES

04.
THERMALLY COOL
ILLUMINATION

9 9
 Retractor-based and Aspirator-based Illumination

Eikon PhotonSaber Y PhotonSaber F

Delivering thermally cool illumination deep into the surgical cavity

10 10
 PhotonBlade
Dynamic Precision Illuminator
with Enhanced Energy

Uniform, thermally cool

Illumination

Precise energy delivery

Low thermal spread

No proprietary generator
required

11 11
PhotonBlade
Industry-Leading Precision Illumination and Visualization
State of the Art Cutting and Coagulation

12
12
PhotonVue
Fluorescence Imaging
Delivering Results for Surgeons
with Fluorescence Imaging.

Responsible Innovation.

13
13
Invuitys System delivers meaningful clinical and economic
benefits

precision / efficiency / safety

Identify critical structures & Improve OR workflow & Avoid preventable errors
vessels efficiency & never Events
Enable fewer/smaller Reduce anesthesia time Prevent burns & OR
incisions fires

14
14
Initial US Beachhead Specialties TAM $1.25B

15 *Company estimate 15
15
16
16
 Commercial Strategy and
Financial Overview

17
Commercialization
Strategy
Growing customer base 845
accounts Q3 2017 vs. 700 Q3
2016

Expand deeper to new surgical

procedures and specialties

Add new products

Drive procedure volumes ~YTD

2017 91,000 procedures vs. YTD
2016 67,000 procedures

Top down marketing programs

18
 Surgeon Certification and Training Program on
Oncoplastic Techniques
Womens Health FocusBreast, Thyroid,
Gynecology
Center of Excellence Certification and Designation

Online External Marketing Internal Marketing

Hidden Scar Centers of Radio Spots On-hold message

Excellence Finder at Print Ads Waiting Room Patient Education
BreastCancerSurgery.com Billboard Ads Video
Hidden Scar Certified Surgeon Media Relations/PR Lobby/Waiting Room Displays and
Finder at Wall Posters
Newsletter Templates
BreastCancerSurgery.com Patient Education Brochures
Website templates
My Hidden Scar Microsite at
MyHiddenScar.com Patient Education Presentation
Social media (Facebook, Twitter, Referral Letters
Pinterest)

19
 Topline Growth Total Revenue

20
 Topline Growth Single Use Revenue

21
 Visionary Surgery

22